Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
about
Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacyInfection with hepatitis C virus. Intravenous gammaglobulin may still infect patientsSafety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies.The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.The use of chromatography to manufacture purer and safer plasma products.Intravenous immunoglobulin: regulatory perspectives on use and supply.Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasmaIntravenous immune globulins: an update for clinicians.Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.Hepatitis C: progress and problems.Human Immunoglobulins for intravenous use and hepatitis C viral transmission.The safety of RhIG in the prevention of haemolytic disease of the newborn.A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C.Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.Causality assessment of suspected virus transmission by human plasma products.Prevalence of TT virus in plasma pools and blood products.
P2860
Q27027732-57560F2D-1433-4CC6-9E77-6D2BCC34F7E6Q27486885-29A8C09A-841A-430F-9F54-277291B215B3Q33762502-1ADCE187-3FC4-4B44-9C53-F613840069CDQ33798451-31C9E5E2-1CD9-484F-8921-D9DE07F19EFDQ33799039-C2A64FCD-E5AD-49E6-8B88-F5032A866F46Q34187883-C0A45535-536C-413E-B723-45F27BDFB2F1Q34216781-FBC1C513-CBAB-4291-B832-8B9FE33CAA7CQ34337134-83D8091C-187D-4A4F-8E63-9475BE2AFA1AQ35542385-E674B2DA-4B08-4108-A656-288A73BA7E2CQ36074636-37FB97CF-BB4C-4C2F-9AC2-D4EF09B03B7DQ36642065-06774C89-E242-4FC9-99F8-74C0E31355C0Q36932236-E0E3DF5A-BB49-4B51-BFEF-D4E5FE2F65C7Q36951785-B7D20D2E-4FA5-41CC-B1D9-38E77024CABAQ37439266-4B7227C4-1DE5-4B95-8DBB-3113428385FEQ38188031-777FE6D7-D2A6-488B-9E4B-6C4E40A2BC7EQ42654339-9FAD5E89-84E0-4CC5-A8EA-122356CD5593Q44386886-8DF125C2-9965-4556-B4A8-08B7149A79A3Q45736204-8DE08249-B09A-4626-8E09-0A95A0AA9040Q45747639-EE1798A2-2850-47F0-BEC8-2B83B30AE201
P2860
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@en
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@nl
type
label
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@en
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@nl
prefLabel
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@en
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@nl
P2093
P1433
P1476
Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
@en
P2093
P304
P356
10.1046/J.1537-2995.1992.32993110753.X
P577
1992-11-01T00:00:00Z